| Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda 2005 · AQ + AS · Patients aged 6 months or older with uncomplicated Plasmodium falciparum malaria; both sexes, not pregnant | 4 mg/kg | 3 days | 731 |
| Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial 2020 · PZQ+DHP · School-going children aged 7–17 years with Schistosoma mansoni intestinal schistosomiasis in rural Tanzania | 40 mg | 3 days | 298 |
| A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy 2008 · artesunate (AS7) · Pregnant women in the second or third trimester with acute uncomplicated Plasmodium falciparum malaria | 2 mg/kg | 7 days | 128 |
| Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria 1997 · AM · Patients with uncomplicated falciparum malaria | 500 mg | 1 day | 117 |
| Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo 2006 · AL (artemether-lumefantrine) · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria who weighed at least 10 kg | 40 mg | 3 days | 106 |
| Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo 2006 · AS + AQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 101 |
| Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo 2006 · AS + SP · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 91 |
| Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand 2003 · Group A (DNP) · Adults older than 14 years and over 40 kg with acute uncomplicated falciparum malaria | 320 mg | 1 day | 89 |
| Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania 2007 · AS+AQ (Mlimba site) · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 76 |
| The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam 2012 · artemisinin-piperaquine (ARPQ) · Patients aged 5–60 years with uncomplicated Plasmodium falciparum malaria | 2.8 mg/kg | 2 days | 63 |
| Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia 2007 · Artesunate/Amodiaquine · People aged 1–65 with uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 42 |
| Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand 2003 · Group B (Coartem/Riamet) · Adults older than 14 years and over 40 kg with acute uncomplicated falciparum malaria | 40 mg | 3 days | 41 |
| Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens 2002 · group A · adult male and female Vietnamese patients with uncomplicated falciparum malaria | 500 mg | 5 days | 40 |
| Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients 2003 · beta-cyclodextrin-artemisinin complex group · Patients with uncomplicated falciparum malaria | 300 mg | 5 days | — |
| Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients 2003 · commercial reference preparation (Artemisinin 250) group · Patients with uncomplicated falciparum malaria | 500 mg | 5 days | — |
| Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria 1998 · oral treatment · adult Vietnamese men with uncomplicated falciparum malaria | 500 mg | 5 days | — |
| Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial 2023 · dihydroartemisinin–piperaquine group · Pregnant women of any age with a viable singleton pregnancy at 16–28 weeks’ gestation in malaria-endemic areas of Malawi, Tanzania, or Kenya | 40 mg | 131 days | 1,561 |
| Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial 2023 · dihydroartemisinin–piperaquine plus azithromycin group · Pregnant women of any age with a viable singleton pregnancy at 16–28 weeks’ gestation in malaria-endemic areas of Malawi, Tanzania, or Kenya | 40 mg | 131 days | 1,558 |
| A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial 2011 · DHAPQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria (12–59 months at sites using CD+A) | 2.25 mg/kg | 3 days | 1,475 |
| A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial 2011 · ASAQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria (12–59 months at sites using CD+A) | 2.8 mg/kg | 3 days | 1,002 |
| An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia 2010 · DHA/PQP · Males and females aged 3 months to 65 years with uncomplicated, microscopically confirmed falciparum or mixed malaria; Indian participants were aged 18 years or older | 2.25 mg/kg | 3 days | 767 |
| Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children 2019 · DHA-PQ group · Children aged 2.33–58.1 months in Burkina Faso, apparently healthy and living in an area of intense seasonal malaria transmission | 2 mg/kg | 90 days | 754 |
| A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages 2018 · Intervention (early MDA) · Residents of four Cambodian forest-fringe villages; all ages except infants under 6 months, pregnant or lactating women, and people with acute health problems | 7 mg/kg | 90 days | 668 |
| Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial 2015 · Intermittent preventive treatment with dihydroartemisinin–piperaquine · HIV-negative pregnant women, 16–32 weeks’ gestation, without a stated diagnosis. | 80 mg | — | 516 |
| Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial 2009 · AS-SMP 3 days · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded | 200 mg | 3 days | 476 |
| Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial 2009 · AS-SMP 24 hours · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded | 200 mg | 2 days | 458 |
| Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial 2009 · AL 3 days · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded | 40 mg | 3 days | 450 |
| An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia 2010 · AS+MQ · Males and females aged 3 months to 65 years with uncomplicated, microscopically confirmed falciparum or mixed malaria; Indian participants were aged 18 years or older | 4 mg/kg | 3 days | 381 |
| Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial 2010 · AQ3-AS3 · Infants aged 5–16 weeks at enrolment in rural western Kenya | 25 mg | 3 days | 347 |
| Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial 2010 · SP-AS3 · Infants aged 5–16 weeks at enrolment in rural western Kenya | 25 mg | 3 days | 339 |
| A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru 2007 · DHA-PPQ · Patients aged 5–60 with uncomplicated Plasmodium falciparum malaria | 2.1 mg/kg | 3 days | 262 |
| A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru 2007 · MAS3 · Patients aged 5–60 with uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 260 |
| Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial 2014 · artemisinin-naphthoquine · Children aged 0.5–5 years with uncomplicated P. falciparum or P. vivax malaria | 20 mg/kg | 3 days | 127 |
| A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy 2008 · artemether-lumefantrine (AL) · Pregnant women in the second or third trimester with acute uncomplicated Plasmodium falciparum malaria | 40 mg | 3 days | 125 |
| A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children 2008 · ASAQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria | 50 mg | 3 days | 123 |
| A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children 2008 · AL · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria | 40 mg | 3 days | 123 |
| [A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco®) and artemether-lumefantrine (Coartem®) in the treatment of uncomplicated malaria in Benin] 2012 · Arco® group · Children with uncomplicated falciparum malaria; age range and sex not specified | 125 mg | 1 day | 84 |
| Population pharmacokinetics of artesunate and amodiaquine in African children 2009 · AS+AQ (loose combination) · Children aged 6 months to 5 years, both sexes, with acute uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 70 |
| Population pharmacokinetics of artesunate and amodiaquine in African children 2009 · AS/AQ (fixed-dose combination) · Children aged 6 months to 5 years, both sexes, with acute uncomplicated Plasmodium falciparum malaria | 4 mg/kg | 3 days | 70 |
| Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand 2008 · Group A (Artequick) · Adults aged 15 years or older, weighing at least 40 kg, with acute uncomplicated falciparum malaria | 3.2 mg/kg | 3 days | 65 |
| Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in Calabar, Nigeria 2012 · Group B · Adults and adolescents aged 15 years or older with uncomplicated falciparum malaria | 250 mg | 1 day | 35 |
| A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women 2007 · SP plus artesunate · Pregnant women aged 15–49 with uncomplicated Plasmodium falciparum infection, 14–26 weeks’ gestation | 200 mg | — | 47 |
| Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial 2009 · MB-AS group · Children aged 6–10 years with uncomplicated falciparum malaria | 4 mg/kg | 3 days | 61 |
| Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial 2009 · AS-AQ group · Children aged 6–10 years with uncomplicated falciparum malaria | 4 mg/kg | 3 days | 61 |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study 2011 · T1 (micronized artemisinin powder, test formulation) · Healthy Vietnamese men aged 18–55 years | 160 mg | 1 day | 15 |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study 2011 · T2 (reference Vietnamese low-dose formulation) · Healthy Vietnamese men aged 18–55 years | 160 mg | 1 day | 15 |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study 2011 · T3 (reference Vietnamese dose-strength formulation) · Healthy Vietnamese men aged 18–55 years | 500 mg | 1 day | 15 |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study 2011 · T4 (fixed artemisinin-piperaquine tablet formulation) · Healthy Vietnamese men aged 18–55 years | 160 mg | 1 day | 15 |
| Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers 2001 · Group AS · Healthy Vietnamese males | 500 mg | 11 days | 10 |
| Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers 2001 · Group AM · Healthy Vietnamese males | 500 mg | 11 days | 10 |
| Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria 2002 · Artemisinin 500 mg daily for 3 days followed by mefloquine on day 4 · Male and female patients with Plasmodium falciparum malaria | 500 mg | 3 days | — |
| Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria 2002 · Artemisinin 500 mg daily for 3 days plus mefloquine on day 1 · Male and female patients with Plasmodium falciparum malaria | 500 mg | 3 days | — |
| A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction 2005 · Daily single-dose regimen · Healthy males | 500 mg | 24 days | — |
| Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria 1996 · AQ · Patients with uncomplicated falciparum malaria; age and sex not specified | 20 mg/kg | 4 days | — |
| Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria 1996 · AD · Patients with uncomplicated falciparum malaria; age and sex not specified | 20 mg/kg | 4 days | — |
| The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum 2009 · AS/AQ (fixed) · Children aged 6 months to 5 years with acute uncomplicated Plasmodium falciparum malaria | 25 mg | 3 days | 375 |
| The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum 2009 · AS+AQ (loose) · Children aged 6 months to 5 years with acute uncomplicated Plasmodium falciparum malaria | 50 mg | 3 days | 375 |
| Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention 2017 · HIV-uninfected pregnant women receiving DHA-piperaquine · Pregnant HIV-uninfected women enrolled between 12 and 28 weeks gestation | 40 mg | 3 days | 31 |
| Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol 2014 · Arm B · Healthy male and nonpregnant female volunteers aged 18–55 years | 60 mg | 9 weeks | 30 |
| Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention 2017 · HIV-uninfected non-pregnant women receiving DHA-piperaquine · HIV-uninfected non-pregnant women at least 12 weeks postpartum | 40 mg | 3 days | 30 |
| Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention 2017 · HIV-infected pregnant women receiving EFV-based ART and DHA-piperaquine · Pregnant HIV-infected women receiving EFV-based antiretroviral therapy | 40 mg | 3 days | 27 |
| Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol 2014 · Arm A · Healthy male and nonpregnant female volunteers aged 18–55 years | 60 mg | 93 days | 26 |
| [Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis] 2002 · treated group · Patients with lupus nephritis whose disease was inactive after corticosterone and cyclophosphamide therapy | 600 mg | 3 years | 31 |